---
figid: PMC5445933__nihms857850f3
figlink: /pmc/articles/PMC5445933/figure/F3/
number: Fig. 3
caption: The main pathways altered in GEMMs of cutaneous melanoma. The principal oncogenic
  modifications introduced in mouse models of melanoma involve the activation of RAS/RAF/MEK/ERK
  and phosphoinositide-3 kinase (PI3K) pathways, the most frequently altered pathways
  in human melanomas. Stimulation of receptor tyrosine kinases (RTK) by binding of
  growth factors (GF) leads to the activation of these pathways resulting in induction
  of proliferation and/or migration and invasion. Alternatively, RAS/RAF/MEK/ERK pathway
  can be induced by direct activation of RAF proteins by G protein-coupled receptors
  (GPCR). Deletion of the tumor suppressor phosphatase and tensin homolog deleted
  on chromosome 10 (PTEN) can also indirectly activate PI3K pathway. In addition,
  cell cycle progression can be induced by the oncogenic activation of cyclin-dependent
  kinase 4 (CDK4) or the inactivation of the tumor suppressors cyclin-dependent kinase
  inhibitor 2A (CDKN2A) or p53. The specific allelic modifications available in mouse
  models of melanoma are highlighted in red (also see ).
pmcid: PMC5445933
papertitle: Genetically Engineered Mouse Models of Melanoma.
reftext: Eva PÃ©rez-Guijarro, et al. Cancer. ;123(Suppl 11):2089-2103.
pmc_ranked_result_index: '133184'
pathway_score: 0.9634869
filename: nihms857850f3.jpg
figtitle: Main pathways altered in GEMMs of cutaneous melanoma
year: ''
organisms:
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5445933__nihms857850f3.html
  '@type': Dataset
  description: The main pathways altered in GEMMs of cutaneous melanoma. The principal
    oncogenic modifications introduced in mouse models of melanoma involve the activation
    of RAS/RAF/MEK/ERK and phosphoinositide-3 kinase (PI3K) pathways, the most frequently
    altered pathways in human melanomas. Stimulation of receptor tyrosine kinases
    (RTK) by binding of growth factors (GF) leads to the activation of these pathways
    resulting in induction of proliferation and/or migration and invasion. Alternatively,
    RAS/RAF/MEK/ERK pathway can be induced by direct activation of RAF proteins by
    G protein-coupled receptors (GPCR). Deletion of the tumor suppressor phosphatase
    and tensin homolog deleted on chromosome 10 (PTEN) can also indirectly activate
    PI3K pathway. In addition, cell cycle progression can be induced by the oncogenic
    activation of cyclin-dependent kinase 4 (CDK4) or the inactivation of the tumor
    suppressors cyclin-dependent kinase inhibitor 2A (CDKN2A) or p53. The specific
    allelic modifications available in mouse models of melanoma are highlighted in
    red (also see ).
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - BRAF
  - AKT2
  - PIK3CG
  - CDK2
  - CDKN2A
  - HGF
  - PIK3R6
  - PIK3R3
  - PTEN
  - CCNA2
  - PIK3CB
  - PIK3R5
  - PIK3R4
  - PIK3CA
  - CCND2
  - PIK3CD
  - CCNA1
  - CCND1
  - GRM1
  - AKT1
  - NRAS
  - RET
  - MDM2
  - MAP2K1
  - MAP2K2
  - MTOR
  - ARAF
  - RAF1
  - NMUR1
  - AKT3
  - TP53
  - KRAS
  - MAPK1
  - MAPK3
  - CCND3
  - HRAS
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
genes:
- word: BRAF
  symbol: BRAF
  source: hgnc_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: CDK2
  symbol: CDK2
  source: hgnc_symbol
  hgnc_symbol: CDK2
  entrez: '1017'
- word: CDKN2A
  symbol: CDKN2A
  source: hgnc_symbol
  hgnc_symbol: CDKN2A
  entrez: '1029'
- word: HGF/SF-Tg
  symbol: HGF
  source: hgnc_symbol
  hgnc_symbol: HGF
  entrez: '3082'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: PTEN
  symbol: PTEN
  source: hgnc_symbol
  hgnc_symbol: PTEN
  entrez: '5728'
- word: CyclinA
  symbol: Cyclin_A
  source: bioentities_symbol
  hgnc_symbol: CCNA2
  entrez: '890'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: CyclinD
  symbol: Cyclin_D
  source: bioentities_symbol
  hgnc_symbol: CCND2
  entrez: '894'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: CyclinA
  symbol: Cyclin_A
  source: bioentities_symbol
  hgnc_symbol: CCNA1
  entrez: '8900'
- word: CyclinD
  symbol: Cyclin_D
  source: bioentities_symbol
  hgnc_symbol: CCND1
  entrez: '595'
- word: Grm1
  symbol: GRM1
  source: hgnc_symbol
  hgnc_symbol: GRM1
  entrez: '2911'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: Ret
  symbol: RET
  source: hgnc_symbol
  hgnc_symbol: RET
  entrez: '5979'
- word: Ink4a/Arft,Inkda/Arffor/on
  symbol: INK4a
  source: hgnc_alias_symbol
  hgnc_symbol: CDKN2A
  entrez: '1029'
- word: MDM2
  symbol: MDM2
  source: hgnc_symbol
  hgnc_symbol: MDM2
  entrez: '4193'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: P14ARF
  symbol: p14ARF
  source: hgnc_alias_symbol
  hgnc_symbol: CDKN2A
  entrez: '1029'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: GPCR
  symbol: GPC-R
  source: hgnc_alias_symbol
  hgnc_symbol: NMUR1
  entrez: '10316'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: p53
  symbol: p53
  source: hgnc_alias_symbol
  hgnc_symbol: TP53
  entrez: '7157'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: CyclinD
  symbol: Cyclin_D
  source: bioentities_symbol
  hgnc_symbol: CCND3
  entrez: '896'
- word: p19Arf
  symbol: p19Arf
  source: hgnc_alias_symbol
  hgnc_symbol: CDKN2A
  entrez: '1029'
- word: p16
  symbol: p16
  source: hgnc_alias_symbol
  hgnc_symbol: CDKN2A
  entrez: '1029'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: p16INK4A
  symbol: p16INK4a
  source: hgnc_alias_symbol
  hgnc_symbol: CDKN2A
  entrez: '1029'
chemicals: []
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Cardiomyopathy
  source: ''
  identifier: ''
- word: Lung cancer
  source: ''
  identifier: ''
- word: Noonan syndrome
  source: ''
  identifier: ''
---
